InnoCare's orelabrutinib cuts CLL/SLL progression risk by 68% in Phase 3
InnoCare Pharma has announced the publication in Signal Transduction and Targeted Therapy (STTT) of full Phase 3 results for its BTK inhibitor orelabrutinib in treatment-naive chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL). The trial, assessed by an independent review committee, found orelabrutinib reduced the risk of disease progression or death by 68% compared with chemoimmunotherapy, with a hazard ratio of 0.32 (p < 0.0001).
The overall response rate in the orelabrutinib arm reached 90.1%, against 79.2% in the control arm. A post-hoc analysis at 30-month follow-up put the complete response rate at 12.1% in the orelabrutinib group, and the duration of response also favoured the investigational arm, with a hazard ratio of 0.30. The clinical team noted consistent benefit across all prespecified subgroups, including patients with adverse molecular features such as del(11q), unmutated IGHV, and bulky disease.
Safety and quality of life
On safety, InnoCare reported that any-grade treatment-related adverse events in the orelabrutinib arm were broadly comparable to those in the control group, a result the company characterises as notable given that the median treatment duration in the orelabrutinib arm (19.3 months) was nearly four times longer than in the chemoimmunotherapy arm (5.2 months). Grade 3 or higher adverse events were less frequent in the orelabrutinib group, and the trial recorded no treatment-related atrial fibrillation, major bleeding events, or second primary malignancies. Patient-reported quality-of-life data favoured orelabrutinib from cycle 16 onwards, with an increasing numerical difference over time.
Orelabrutinib is already approved for first-line CLL/SLL in China and was added to the National Reimbursement Drug List in 2025, giving it broad domestic coverage. STTT, which published the full paper, is a Nature Portfolio journal and carried a journal impact factor of 81.2 as of June 2026.
Market context and competitive positioning
The BTK inhibitor space in CLL/SLL is highly competitive. Ibrutinib, the first-generation covalent BTK inhibitor, was broadly succeeded in clinical practice by acalabrutinib and zanubrutinib, both of which demonstrated improved cardiovascular tolerability profiles. Orelabrutinib is a next-generation covalent BTK inhibitor developed specifically to reduce off-target kinase activity, and the absence of atrial fibrillation events in this trial will attract attention from haematologists weighing the class effects of earlier agents.
Outside China, the drug does not yet hold regulatory approval, and InnoCare has not disclosed a timeline or strategy for submissions to the US FDA or EMA in this release. That gap matters commercially: Western markets account for the majority of diagnosed CLL cases, and the competitive window for a new covalent BTK inhibitor is narrowing as non-covalent agents such as pirtobrutinib, approved by the FDA in 2023 for relapsed and refractory settings, move into earlier lines of therapy. Whether InnoCare pursues a licensing or co-development partnership for ex-China rights remains an open question that investors will be watching closely.
For now, the STTT publication serves primarily to establish peer-reviewed credibility for a dataset that underpins the drug's existing Chinese approval. The lead authors are affiliated with Jiangsu Province Hospital and the Chinese Academy of Medical Sciences, reflecting the trial's Chinese investigator base.